Absci Corporation (ABSI)

Market Cap	446.82M +16.6%
Revenue (ttm)	2.80M -38.2%
Net Income	-115.18M
EPS	-0.84
Shares Out	153.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,823,328
Open	2.930
Previous Close	2.960
Day's Range	2.800 - 2.980
52-Week Range	2.011 - 5.228
Beta	2.01
Analysts	Strong Buy
Price Target	7.47 (+155.82%)
Earnings Date	May 12, 2026

About ABSI

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 22, 2021
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: ABSI
• Website: https://www.absci.com

Financial Performance

In 2025, Absci's revenue was $2.80 million, a decrease of -38.24% compared to the previous year's $4.53 million. Losses were -$115.18 million, 11.7% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $7.47, which is an increase of 155.82% from the latest price.

Price Target

$7.47

(155.82% upside)

Analyst Consensus: Strong Buy